Liquid Biopsies

Capital Biosciences offers liquid biopsies procured from cancer patients with verified markers and mutations. Control cfDNA derived from liquid biopsies is also available. Total genomic DNA was amplified using whole genome amplification method. Mutations have been validated by targeted sequencing. In this panel both normal and circulating tumor DNA (ctDNA) are present in the ratios that represent cancer stage. Panels for different stages of particular cancers can be generated. All human samples available from Capital Biosciences are legally procured under the laws and regulations of the country of acquisition, and in accordance with the USA laws related to use of human materials. All donors are protected by anonymity and Informed Consent, which clearly states scientific research purposes and possible benefits to scientific discovery and humanity. All clinical materials are obtained following official protocols, with Institutional Review Board (IRB) approval, that operates in accordance with the current Federal Regulations. Capital Biosciences, Inc. is a trusted provider of human specimen to pharmaceutical and biotech companies, academic centers and hospitals since 2006. Human specimens and relevant clinical information is delivered to our customers fully de-identified. All provided specimens are suitable for commercial research and development. Mutations in the following Cancer Genes will be determined by NGS: ABL1 AKT1 ALK APC AR ATM BRAF CDH1 CDK4 CDK6 CDKN2A CSF1R CTNNB1 DNMT3A EGFR ERBB2 ERBB4 ESR1 EZH2 FBZW7 FGFR1 FGFR2 FGFR3 FLT3 GNA11 GNAQ GNAS HNF1A HRAS IDH1 IDH2 JAK2 JAK3 KDR KIT KRAS MAP2K1 MET MLH1 MPL MYC NPM1 NRAS PDGFRA PIK3CA PIK3RI PTEN PTPN11 RB1 RET SMAD4 SMARCB1 SMO SRC STK11 TERT